Physician profile
Venugopal Botla
NPI 1689656357
$6,389.80
in general payments reported to CMS, 2019-2025
31 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $494 · 2021: $165 · 2022: $515 · 2023: $1,261 · 2024: $1,727 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,698 · Travel and Lodging: $38.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,697.88 |
| Travel and Lodging | $38.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $1,167.36 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $1,066.33 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $712.41 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $588.21 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Calliditas Therapeutics US INC. | $396.86 | 2023-2025 | Tarpeyo |
| Avenu Medical INC. | $386.22 | 2020 | |
| Horizon Therapeutics Plc | $236.47 | 2023 | Krystexxa |
| Vifor Pharma, INC. | $207.38 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $192.60 | 2022-2025 | Terlivaz, Acthar |
| Ardelyx, INC. | $180.26 | 2024 | Xphozah 30 Mg, Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.99 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $135.45 | 2024-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $123.52 | 2022 | |
| Akebia Therapeutics INC | $121.41 | 2019-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $106.25 | 2022-2023 | Lupkynis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $102.49 | 2022-2024 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $88.01 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $55.57 | 2019-2023 | Rayaldee |
| Novo Nordisk INC | $43.64 | 2023-2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $38.38 | 2025 | |
| Lilly USA, LLC | $37.77 | 2024-2025 | Jardiance |
| Mozarc Medical US LLC | $35.51 | 2024 | Chameleon |
| Merck Sharp & Dohme LLC | $34.82 | 2025 | Prevymis |
| Bard Peripheral Vascular, INC. | $28.38 | 2019 | |
| Genzyme Corporation | $26.73 | 2019 | |
| Kyowa Kirin, INC. | $22.97 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.00 | 2022 | |
| Apellis Pharmaceuticals, INC. | $19.01 | 2025 | Empaveli |
| Covidien LP | $16.67 | 2020 | |
| Nxstage Medical, INC. | $13.61 | 2023 | Nxstage Cartridge Express, Nxstage System One |
| Medtronic, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venugopal Botla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.